Metformin treatment for Type 2 diabetes in pregnancy?

被引:22
|
作者
Simmons, David [1 ,2 ]
机构
[1] Addenbrookes Hosp, Wolfson Diabet & Endocrinol Clin, Inst Metab Sci, Cambridge Univ Hosp NHS Fdn Trust, Cambridge CB2 2QQ, England
[2] Univ Melbourne, Dept Rural Hlth, Shepparton, Vic, Australia
关键词
Type; 2; diabetes; Pregnancy; Metformin; Glucose; Malformation; Insulin; Macrosomia; Pre-eclampsia; POLYCYSTIC-OVARY-SYNDROME; ORAL HYPOGLYCEMIC AGENTS; RELEASE METFORMIN; HUMAN-MILK; WOMEN; INSULIN; MELLITUS; THERAPY; RISK; MANAGEMENT;
D O I
10.1016/j.beem.2010.05.002
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Metformin lowers blood glucose by reducing hepatic glucose output, increasing insulin sensitivity and enhancing peripheral glucose uptake. Metformin is widely used in women with Type 2 diabetes of child-bearing age, many of whom become pregnant. Studies to date in Type 2 diabetes in pregnancy, gestational diabetes and polycystic ovarian syndrome are reassuring. Metformin is not considered teratogenic. There is sufficient evidence that metformin is safe used throughout pregnancy, with no worsening of obstetric or perinatal outcomes. Women may benefit from the lesser weight gain. The long-term risks to the offspring remain inadequately researched, with no evidence of harm up to 2 years, and no suggestions of later complications in countries using metformin for many years. Metformin is recommended for use in pregnancies complicated by Type 2 diabetes, but women should be informed of the evidence regarding its associated risks and benefits to enable an informed choice over its use. (C) 2010 Elsevier Ltd. All rights reserved.
引用
收藏
页码:625 / 634
页数:10
相关论文
共 50 条
  • [21] Use of metformin is associated with lower incidence of cancer in patients with type 2 diabetes
    Muszynska-Oglaza, Alicja
    Zarzycka-Lindner, Grazyna
    Olejniczak, Henryka
    Polaszewska-Muszynska, Miroslawa
    Junik, Roman
    ENDOKRYNOLOGIA POLSKA, 2017, 68 (06) : 652 - +
  • [22] Metformin versus insulin treatment in gestational diabetes in pregnancy in a developing country. A randomized control trial
    Ainuddin, Jahanara
    Karim, Nasim
    Hasan, Anjum Ara
    Naqvi, Sanower Ali
    DIABETES RESEARCH AND CLINICAL PRACTICE, 2015, 107 (02) : 290 - 299
  • [23] Management of Type 2 diabetes and pregnancy
    Casson, Ian F.
    WOMENS HEALTH, 2007, 3 (05) : 593 - 602
  • [24] Effects of metformin, rosiglitazone and insulin on bone metabolism in patients with type 2 diabetes
    Stage, Tore Bjerregaard
    Christensen, Mette-Marie Hougaard
    Jorgensen, Niklas Rye
    Beck-Nielsen, Henning
    Brosen, Kim
    Gram, Jeppe
    Frost, Morten
    BONE, 2018, 112 : 35 - 41
  • [25] Type 1 Diabetes in Pregnancy
    McCance, David R.
    Casey, Claire
    ENDOCRINOLOGY AND METABOLISM CLINICS OF NORTH AMERICA, 2019, 48 (03) : 495 - +
  • [26] Association of pregnancy outcomes in women with type 2 diabetes treated with metformin versus insulin when becoming pregnant
    Lin, Shu-Fu
    Chang, Shang-Hung
    Kuo, Chang-Fu
    Lin, Wan-Ting
    Chiou, Meng-Jiun
    Huang, Yu-Tung
    BMC PREGNANCY AND CHILDBIRTH, 2020, 20 (01)
  • [27] Metformin in pregnancy
    Bijok, Julia
    Binkowska, Malgorzata
    Jakiel, Grzegorz
    GINEKOLOGIA POLSKA, 2014, 85 (07) : 527 - 531
  • [28] Dapagliflozin add-on to metformin in type 2 diabetes inadequately controlled with metformin: a randomized, double-blind, placebo-controlled 102-week trial
    Bailey, Clifford J.
    Gross, Jorge L.
    Hennicken, Delphine
    Iqbal, Nayyar
    Mansfield, Traci A.
    List, James F.
    BMC MEDICINE, 2013, 11
  • [29] Treatment intensification in patients with type 2 diabetes who failed metformin monotherapy
    Fu, A. Z.
    Qiu, Y.
    Davies, M. J.
    Radican, L.
    Engel, S. S.
    DIABETES OBESITY & METABOLISM, 2011, 13 (08) : 765 - 769
  • [30] Canagliflozin plus metformin ER for the treatment of type 2 diabetes: the evidence to date
    Tomlinson, Brian
    Li, Yan-Hong
    EXPERT OPINION ON PHARMACOTHERAPY, 2023, 24 (18) : 1937 - 1947